Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP874336.RA7i3Ql2kwn50Tn2gP5BrGvMJVYpPmOSW0v1qEPzh7s1I130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP874336.RA7i3Ql2kwn50Tn2gP5BrGvMJVYpPmOSW0v1qEPzh7s1I130_assertion type Assertion NP874336.RA7i3Ql2kwn50Tn2gP5BrGvMJVYpPmOSW0v1qEPzh7s1I130_head.
- NP874336.RA7i3Ql2kwn50Tn2gP5BrGvMJVYpPmOSW0v1qEPzh7s1I130_assertion description "[In the European LeukemiaNet (ELN) favorable-risk group (patients with CN-AML who have mutated CEBPA and/or mutated NPM1 without FLT3 internal tandem duplication [FLT3-ITD]), TET2-mutated patients had shorter event-free survival (EFS; P < .001) because of a lower complete remission (CR) rate (P = .007), and shorter disease-free survival (DFS; P = .003), and also had shorter overall survival (P = .001) compared with TET2-wt patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP874336.RA7i3Ql2kwn50Tn2gP5BrGvMJVYpPmOSW0v1qEPzh7s1I130_provenance.
- NP874336.RA7i3Ql2kwn50Tn2gP5BrGvMJVYpPmOSW0v1qEPzh7s1I130_assertion evidence source_evidence_literature NP874336.RA7i3Ql2kwn50Tn2gP5BrGvMJVYpPmOSW0v1qEPzh7s1I130_provenance.
- NP874336.RA7i3Ql2kwn50Tn2gP5BrGvMJVYpPmOSW0v1qEPzh7s1I130_assertion SIO_000772 21343549 NP874336.RA7i3Ql2kwn50Tn2gP5BrGvMJVYpPmOSW0v1qEPzh7s1I130_provenance.
- NP874336.RA7i3Ql2kwn50Tn2gP5BrGvMJVYpPmOSW0v1qEPzh7s1I130_assertion wasDerivedFrom befree-2016 NP874336.RA7i3Ql2kwn50Tn2gP5BrGvMJVYpPmOSW0v1qEPzh7s1I130_provenance.
- NP874336.RA7i3Ql2kwn50Tn2gP5BrGvMJVYpPmOSW0v1qEPzh7s1I130_assertion wasGeneratedBy ECO_0000203 NP874336.RA7i3Ql2kwn50Tn2gP5BrGvMJVYpPmOSW0v1qEPzh7s1I130_provenance.